See also: Generic Coreg
Coreg CR is a brand name of carvedilol, approved by the FDA in the following formulation(s):
COREG CR (carvedilol phosphate - capsule, extended release; oral)
Manufacturer: SB PHARMCO
Approval date: October 20, 2006
Strength(s): 10MG, 20MG, 40MG [RLD], 80MG
Has a generic version of Coreg CR been approved?
No. There is currently no therapeutically equivalent version of Coreg CR available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Coreg CR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Use of carbazole compounds for the treatment of congestive heart failure
Patent 5,902,821
Issued: May 11, 1999
Inventor(s): Lukas-Laskey; Mary Ann & Ruffolo, Jr.; Robert & Shusterman; Neil & Sponer; Gisbert & Strein; Klaus
Assignee(s): Boehringer Mannheim Pharmaceuticals Corporation Smith Kline Corporation
A method of treatment using carvedilol is disclosed, wherein the carvedilol decreases the mortality caused by congestive heart failure in patients. The patients are titrated with low amounts of carvedilol, with the initial titration dosage being only 10 to 30% of the daily maintenance dose.Patent expiration dates:
- February 7, 2016✓
- February 7, 2016✓
- August 7, 2016✓
- February 7, 2016
Medicinal and/or nutritional microcapsules for oral administration
Patent 6,022,562
Issued: February 8, 2000
Inventor(s): Autant; Pierre & Selles; Jean-Philippe & Soula; Gerard
Assignee(s): Flamel Technologies
The present invention relates to microcapsules for the oral administration of medicinal and/or nutritional active principles (AP), which are smaller than or equal to 1000 .mu.m in size. These microcapsules consist of particles which are coated with a coating material consisting of a mixture of a film-forming polymer derivative, a hydrophobic plasticizer, a functional agent and a nitrogen-containing polymer. These microcapsules are also characterized by their ability to remain in the small intestine for a long time (at least 5 hours) and to allow, during the residence, release and absorption of the AP. The invention also relates to a process for the production of the said microcapsules.Patent expiration dates:
- October 17, 2015✓
- April 17, 2016✓
- October 17, 2015
Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
Patent 7,268,156
Issued: September 11, 2007
Inventor(s): Brook; Christopher S. & Chen; Wei & Spoors; Paul G.
Assignee(s): SB Pharmco Puerto Rico Inc.
The present invention relates to carvedilol phosphate salts, which include novel crystalline forms of carvedilol dihydrogen phosphate (i.e., dihydrogen phosphate salt of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol) and/or carvedilol hydrogen phosphate, etc.), and/or solvates thereof, compositions containing the aforementioned salts and/or solvates, and methods of using the aforementioned salts and/or solvates to treat hypertension, congestive heart failure and angina, etc.Patent expiration dates:
- June 27, 2023✓✓✓
- June 27, 2023✓✓✓
- December 27, 2023✓
- June 27, 2023
Method of treatment for decreasing mortality resulting from congestive heart failure
Patent RE40000
Issued: January 8, 2008
Inventor(s): Lukas-Laskey; Mary Ann & Ruffolo, Jr.; Robert & Shusterman; Neil Howard & Sponer; Gisbert & Strein; Klaus
Assignee(s): SB Pharmco Puerto Rico Inc.
A method of treatment using a compound of Formula I: wherein: R1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl; R2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl; R3 is hydrogen or lower alkyl of up to 6 carbon atoms; R4 is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R4 together with R5 can represent —CH2—O—; X is a valency bond, —CH2, oxygen or sulfur; Ar is selected from phenyl, naphthyl, indanyl and tetrahydronapthyl; R5 and R6 are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a —CONH2— group, lower alkoxy of up to 6 carbon atoms, benzyloxy, lower alkylthio of up to 6 carbon atoms, lower alkysulphinyl of up to 6 carbon atoms and lower alkylsulphonyl of up to 6 carbon atoms; or R5 and R6 together represent methylenedioxy; or a pharmaceutically acceptable salt thereof, alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of ACE inhibitors, diuretics, and digoxin for decreasing mortality resulting from congestive heart failure (CHF) in mammals, particularly humans.Patent expiration dates:
- June 7, 2015✓
- December 7, 2015✓
- June 7, 2015
See also...
- Coreg CR Extended-Release Capsules Consumer Information (Wolters Kluwer)
- Coreg CR Consumer Information (Cerner Multum)
- Coreg CR Advanced Consumer Information (Micromedex)
- Carvedilol Consumer Information (Wolters Kluwer)
- Carvedilol Extended-Release Capsules Consumer Information (Wolters Kluwer)
- Carvedilol Consumer Information (Cerner Multum)
- Carvedilol Advanced Consumer Information (Micromedex)
- Carvedilol AHFS DI Monographs (ASHP)
No comments:
Post a Comment